For instance, a comprehensive exome-wide study involving over 70,000 individuals showed that individuals homozygous for the minor variant rs72613567 T/A of HSD17B13 (Hydroxysteroid 17-beta retinol dehydrogenase 13) experience a reduced risk of hepatic injury associated with PNPLA3 and mitigate the risks of NAFLD, NASH, and cirrhosis by 30% and 49% accordingly [89]. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatotic liver disease.